Intensity of adjuvant chemotherapy regimens and grade III–V toxicities among elderly stage III colon cancer patients
Authors:
- 1 July 2016
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 61, 1-10
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Efficacy and Safety of Single Agent or Combination Adjuvant Chemotherapy in Elderly Patients With Colon Cancer: A Canadian Cancer Institute ExperienceClinical Colorectal Cancer, 2014
- Elderly patients with colorectal cancer: Treatment modalities and survival in France. National data from the ThInDiT cohort studyEuropean Journal of Cancer, 2014
- Administration of adjuvant oxaliplatin to patients with stage III colon cancer is affected by age and hospitalActa Oncologica, 2014
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset AnalysesJournal of Clinical Oncology, 2011
- Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacyAnnals of Oncology, 2011
- Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon CancerJournal of Clinical Oncology, 2011
- Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon CancerJAMA, 2010
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC TrialJournal of Clinical Oncology, 2009
- Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatinCancer, 2007
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerNew England Journal of Medicine, 2005